|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on July 18, 2002; DOI 10.1182/blood-2002-04-1284.
IMMUNOBIOLOGY
From the Laboratory of Immunology, National Institute
for Cancer Research (IST), Genoa; DIMI, University of Genoa; and
Laboratory of Tumor Immunology, Istituto Scientifico San Raffaele,
Milan, Italy.
The engagement of the activating isoforms of C-type lectin
inhibitory receptor (CLIR) or killer Ig-like receptor (KIR) by their
natural ligands, represented by soluble HLA-I (sHLA-I) molecules, induced programmed cell death of natural killer (NK) cells. Indeed, NK
cell apoptosis elicited by either putative HLA-E and HLA-F (sHLA-I
non-A, -B, -C, and -G) or sHLA-I-Cw4 or -Cw3 from untransfected or
-Cw4 or -Cw3 alleles transfected HLA-A It is generally accepted that the major
histocompatibility complex class I-specific inhibitory receptors on
natural killer (NK) cells prevent the lysis of healthy autologous
cells.1-3 This inhibitory receptor superfamily (IRS) can
be subdivided into 2 structural types of molecules. The first one
consists of immunoglobulin (Ig) superfamily receptors (ISIRs), the
other one of C-type lectin inhibitory receptors (CLIRs). IRS engagement
with the appropriate HLA-class I (HLA-I) allele delivers an inhibitory
signal that down-regulates several NK and T-cell functions such
as proinflammatory cytokine production, proliferation, and cytolytic
activity.1-3 Recently, we have demonstrated that IRS
members can function as survival receptors in NK cells. Indeed, the
apoptosis of NK cells induced by soluble HLA-I (sHLA-I), via the
engagement of CD8, is strongly down-regulated by ligation of sHLA-I
with IRS.4
Some members of the IRS include receptors with activating rather than
inhibitory function.1-3 These activating receptors are
represented by the killer cell Ig-like receptor (KIR) family with 2 Ig
domains (KIR2D) with a short cytoplasmic tail (KIR2DS or p50) or by
CLIR isoforms, such as CD94/NKG2C complex, which lack the
immunoreceptor tyrosine-based inhibition motif (ITIM).1-3 KIR2DS and NKG2C associate with a short disulfide-linked homodimer of
the protein called DAP12 that carries a cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM).1-3 It has been
shown that these receptors Monoclonal antibodies and reagents
Indirect immunofluorescence
Isolation and culture of polyclonal and clonal NK cell populations Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were isolated by Ficoll-Hypaque gradient. CD3 CD4 cells were isolated after negative
immunodepletion as described.26 The resulting cell
population was 50% to 70% CD16+ (range of 8 different
experiments) but 99% CD3CD4. Highly
purified CD3CD4 cells were stimulated with
10 µg/mL phytohemagglutinin (PHA) and cultured in 96-well
U-bottomed microplates (Becton Dickinson) with complete medium in the
presence of 100 U/mL recombinant IL-2 (rIL-2) in a final volume of 200 µL per well in the presence of 105-per-well irradiated
allogeneic PBMCs and 5 × 103-per-well 721.221 lymphoblastoid cell line transfected with
HLA-G.26 CD3CD16+
clones were obtained by culturing highly purified
CD3CD4 NK cells under limiting dilution
conditions as previously reported.13,26 Cloning efficiency
was of 5% to 10% calculated as described.27 All
NK cell clones were analyzed for the expression of CD158a (p50.1),
CD158b (p50.2), p50.3 (CD158a and CD158b
but NKVFS1+), CD94/NKG2A (mAb Z199, Serotec), CD16, and
CD56. Each clone was analyzed in a killing assay using the
Fc R+ P815 murine mastocytoma cell line in the presence
of mAb recognizing either KIRs or C-type lectin inhibitory receptors at
the effector-target ratio (E/T) of 20:1 or 2:1 to identify clones with
inhibiting or activating forms of these HLA-I receptors,
respectively.1-3,10-13,22
Soluble HLA-I antigen preparations Soluble HLA-A2, -Cw3, and -Cw4 were prepared from culture supernatant of HLA-I-A, -B,
-C, and -G 721.221 cells transfected with
the corresponding HLA-I alleles 6,28,29 while soluble HLA
non-A, -B, -C, and -G was prepared from culture supernatant of
untransfected 721.221 cells by precipitation with ammonium sulfate,
low-medium pressure chromatography, strong anionic and strong cationic
ion exchange, and gel filtration as described 28,29 and
purified by affinity chromatography on anti-HLA class I mAb W6/32 (10 mg/mL) coupled to cyanogen bromide-activated Sepharose 4B
(Pharmacia). The purity of sHLA-I molecule preparations was
analyzed by 1-dimensional polyacrylamide gel electrophoresis (PAGE) under nonreducing/nondenaturing (Figure 2A) or
reducing/denaturing conditions (not shown) followed by silver
staining.28,29 721.221 untransfected cells appeared to be
faintly stained with W6/32 mAb followed by PE-conjugated GAM antiserum;
thus, in accordance with previous reports,30-36 it is
conceivable that the sHLA-I derived from these cells was represented,
at least in part, by HLA-E and HLA-F molecules.37
Determination of sFasL and IFN- present in supernatant from NK cell clones
incubated for 48 hours with medium alone, or under different
culture conditions as indicated in "Results," was evaluated by
ELISA (Bender MedSystems Diagnostics, Vienna).
Induction and detection of apoptosis Bulk NK cell populations or NK cell clones (105 per milliliter) were cultured in 24-well flat-bottomed plates with culture medium either alone or with different amounts of sHLA-I molecules (0.5 to 4 µg/mL) for different periods (6, 12, 24, 36, 48, 60, 72 hours) at 37°C in a 5% CO2 atmosphere. In some experiments cells were incubated with anti-CD158a or anti-CD158b or anti-CD94 or anti-CD54 mAb for 30 minutes at 4°C, washed, and either used in apoptotic assays (to analyze the effect of the covering of a given activating receptor) or further incubated for different times with 4-per-cell GAM-coated magnetic beads 6,28,29 (to obtain the optimal cross-linking of a given activating receptor). Early apoptotic events were evaluated by annexin V labeling method, and viable apoptotic cells were differentiated from necrotic cells by flow cytometry after PI staining of nonpermeabilized cells.6 Apoptotic cells were identified as annexin V+ PI cells6,28,29; 104 cells per
sample were analyzed and results plotted as the percentage of annexin
V+ cells and PI cells. Apoptosis was also
detected by PI staining after permeabilization (DNA content < 2n) and
by DNA laddering after DNA extraction and agarose gel
electrophoresis.6,28,29
Isolation of RNA, reverse transcription, and PCR amplification Total RNA was isolated from cell pellets by using the RNAzol B (Biotecx Laboratories, Houston, TX) method.28 Complementary DNA (corresponding to 2 µg RNA) was synthesized from oligo(dT)-primed RNA as described.28 The polymerase chain reaction (PCR) mixture was amplified using the following primer sequences: -actin 5'-ACTCCATCATGAAGTGTGACG, -actin
3'-CCTAGTCGTTCGTCCTCATAC (228-bp fragment); FasL
5'-CAAGTCCAACTCAAGGTCCATGCC, FasL 3'-CAGAGAGAGCTCAGATACGTTGAC (350-bp
fragment).6,28 PCR products were size-fractionated by
agarose gel electrophoresis and normalized according to the amount of
-actin detected in the same mRNA sample.
Cytolytic assays Cytolytic activity of CD3CD16+ NK cell
clones was tested in a 4-hour 51Cr-release assay as
previously described.13,22 Polyclonal or clonal
CD3CD16+ NK cell populations, selected for
the expression of activating forms of either KIR and/or CLIR, were used
as effector cells with the FcR+ murine mastocytoma cell
line P815 in the presence of mAb directed against activating receptor
for HLA, at an effector-target ratio (E/T) of 2:1, in a final volume of
200 µL RPMI 1640 medium in V-bottomed microwells.13,22
NK cell-mediated cytolysis was also analyzed against a panel of target
cells including K562 (erythroleukemia), Jurkat (T-cell lymphoma), and
721.221 lymphoblastoid cell line. The effect of cyclosporin A (5, 50, 500 ng/mL) or concanamycin A (0.3-3 µM) on NK cell-mediated
cytolytic activity was analyzed after pretreatment of NK cells for 15 minutes. The optimal concentration for each compound is indicated in
"Results." Cell viability was analyzed after incubation with the
different drugs or the appropriate dilution buffer and was always more
than 98%.
Soluble HLA-I induces NK cell apoptosis upon engagement of the activating isoforms of KIR or C-type lectin inhibitory receptor Besides inhibiting receptors for HLA-I, NK cells express at the cell surface the activating isoforms of these receptors.1-3 It appears that these activating receptors recognize the same HLA-I allele, which can interact with their inhibiting counterparts.1-3,7-13,30 NK cells bearing activating receptor can kill cells expressing the appropriate HLA-I allele,1-3,7-13,30 because their engagement delivers an activating signal that ultimately leads to NK cell degranulation of perforins and granzymes.1-3 Thus, these findings would suggest that the activating receptor for HLA-I is potentially harmful and, thus, control mechanisms that down-regulate activating receptor-mediated function should exist. It is conceivable that apoptosis can represent a useful tool to switch off effector cell-mediated activities.4 Thus, to define these mechanism(s), we first analyzed whether the engagement of activating receptor by its natural ligand, HLA-I, can induce NK cell apoptosis. To this aim, to demonstrate that HLA-I interacting with activating receptor can directly deliver an apoptotic signal, we incubated NK cell clones with the soluble form of HLA-I derived from the lymphoblastoid 721.221 HLA-I cell line either untransfected or stably
transfected with appropriate HLA-I allele35,36 (Figure
1A).
To select NK cells bearing activating receptor, NK cell clones were
first chosen on the basis of the homogeneous expression of receptors
for HLA-I. Secondly, each clone was tested in a killing assay against
the Fc Among the clones analyzed, about 10% expressed activating receptor
isoforms of either KIR or CLIR (35 of 350 tested) (Table 1). In addition, as we have demonstrated
that CD8 ligation with sHLA-I can induce NK cell apoptosis by
interacting with the
To determine whether the activating receptor may deliver an apoptotic
signal in NK cells, only NK cell clones with a dull expression of CD8
were further analyzed. As shown in Figure
2B, sHLA-I-Cw4 allele, the natural
ligand of CD158a, induced apoptosis of the clone 262, which expressed
the activating receptor form of CD158a. Preincubation of NK cells with
anti-CD158a mAb strongly reduced this apoptosis, indicating that the
interaction of sHLA-I-Cw4 with CD158a was necessary to induce cell
death. The finding that the optimal cross-linking of CD158a, achieved
by using anti-CD158a mAb followed by GAM-coated beads, led to NK cell
apoptosis further indicates that the engagement of activating receptor
may induce NK cell death. Noteworthy, the incubation of the NK cell
clone 262 with the sHLA-I-A2 allele, an HLA-I allele that does not
bind CD158a, did not induce apoptosis (Figure 2B), suggesting that the
apoptotic signal can be delivered only when the activating receptor is
engaged by its specific sHLA-I allele. Similar results were obtained
using the NK cell clone A1.25 bearing the activating receptor form of
CD158b and sHLA-I-Cw3 as specific ligand (Figure 2C). Because we have
previously demonstrated that the engagement of CD8 with sHLA-I at the
NK cell surface led to NK cell apoptosis, we further analyzed whether
apoptosis induced by ligation of activating receptor was independent on
CD8-mediated signaling. As shown in Figure 2D, we found that the
covering of CD8 with specific mAb did not affect activating
receptor-induced apoptosis.
Analogous results were obtained using NK cells bearing the activating
receptor forms of CLIR represented by CD94/NKG2 complex (Figure 2E).
However, in this case, we have used as specific sHLA-I the sHLA-I
isolated from HLA-A As depicted in Figure 3, that activating
receptor actually induced apoptosis in NK cells after interaction with
sHLA-I-specific allele was further supported by DNA analysis with PI
(Figure 3B) and DNA laddering (Figure 3C), besides staining of NK cells
with FITC-annexin V (Figure 3A). Indeed, the number of NK cells with a
DNA content less than 2n (apoptotic cells) after covering of activating
receptor form of CLIR (Figure 3Biii) with anti-CLIR mAb was strongly
reduced compared with that found upon incubation of NK cells with sHLA
non-A, -B, -C, and -G (Figure 3Bii; 85% vs 12%). Comparable results
were obtained by DNA laddering (Figure 3C, compare lanes 2 and 3). The
percentage of apoptotic cells was maximal at 4 µg/mL although it was
detectable at 1 µg/mL (Figure 3D). Finally, kinetics of apoptosis
revealed that the optimal incubation time of NK cells with the specific
sHLA-I allele was 48 hours (Figure 3E).
NK cell apoptosis induced by activating receptor of KIR or CLIR is mediated by FasL-Fas interaction It has been shown that FasL-Fas interaction is responsible for inducing apoptosis through the ligation of CD8 by sHLA-I both in T and NK cells.6,15,16,29 Thus, to define which surface receptor is involved in delivering an apoptotic signal upon engagement of activating receptor isoforms of KIR or CLIR, we incubated NK cells with sHLA-I alleles in the presence of either anti-Fas or anti-FasL mAb alone or in combination. As shown in Figure 4A, covering of Fas antigen at the NK cell surface and/or the incubation with anti-FasL mAb strongly reduced the activating receptor-mediated NK cell apoptosis. That FasL was implicated in this phenomenon was further supported by the finding that FasL was present in culture supernatants of NK cells incubated with the appropriate sHLA-I allele (Figure 4B-D). In addition, covering of CD8 with specific mAb did not reduce the amount of sFasL recovered from culture supernatant induced by incubation of the CD8dull NK cell clone A1.25 bearing activating receptor isoform of CD158b with its specific ligand sHLA-Cw3 (Figure 4C). This finding suggests that CD8 is not directly involved in activating receptor-mediated NK cell apoptosis. Furthermore, as shown in Figure 4E, the engagement of the activating receptor CD158a with sHLA-Cw4 (or upon cross-linking with anti-CD158a mAb plus GAM-coated beads) induced a strong increase of mRNA coding for FasL that was abolished by the covering of CD158a with specific mAb. Similar results were obtained by incubating NK cells bearing activating receptor of CD94 with sHLA non-A, -B, -C, and -G ligand (not shown). Altogether, these findings suggest that the engagement of activating receptor by sHLA-I-specific alleles delivers an apoptotic signal through the production of FasL that in turn is secreted in the extracellular milieu and eventually interacts with Fas at the NK cell surface, leading to NK cell apoptosis.
NK cell-mediated apoptosis via activating receptor isoforms of KIR or CLIR is CsA dependent Apoptosis induced by the activating isoforms of KIR and/or CLIR can represent a mechanism that limits cell tissue damage due to activation of NK cells against autologous cells. On the other hand, activating isoforms of KIR and/or CLIR can recognize at the cell surface of autologous tumor cells the corresponding HLA-I allele and, thus, this recognition can trigger target cell lysis. Thus, we analyzed whether the activating receptor-mediated NK cell apoptosis was sensitive to blocking drugs, different from activating receptor-mediated target cell lysis. In this context, it has been shown that NK cells lyse tumor target cells by means of secretion of perforins and granzymes present in intracellular discrete granules and that this process is sensitive to the specific inhibitor of vacuolar type H+-ATPase concanamycin (CMA).24,25 On the other hand, the FasL induction and its consequent secretion, in human NK cells, is strictly dependent on the activation of calcineurin and nuclear factors of activated T cell (NFAT), which in turn are highly cyclosporin A sensitive.23 Thus, we analyzed whether apoptosis and/or cytolysis induced through activating receptor were alternatively sensitive to CsA or CMA.NK cell treatment with CsA, in a dose-dependent fashion, led to a
strong reduction of sHLA-I-mediated apoptosis through ligation of
activating receptor (Figure 5A). Indeed,
the apoptosis induced by ligation of p50.3 on the NK cell clone 12, with either sHLA-Cw3 or with anti-p50 mAb followed by optimal
cross-linking with GAM-coated beads, was reduced by 99% and 92%,
respectively, in the presence of 500 ng/mL CsA (Figure 5A).
Importantly, CsA treatment of NK cells was accompanied by a strong
reduction of the amount of sFasL present in culture supernatant after
ligation of p50.3 with sHLACw3 or with anti-p50 mAb followed by optimal
cross-linking with GAM-coated beads (Figure 5B). Although not shown,
similar results were obtained with NK cell clones bearing the
activating receptor CD158a or CD158b or CD94. By contrast, CMA only
marginally influenced NK cell apoptosis induced by p50.3 (Figure 5C) or
via activating receptor isoforms of CD158a or CD158b or CD94 (not
shown).
As shown in Figure 6A-B, CMA strongly
reduced (by 50%), in a killing assay, lysis of P815 target cells
induced by the engagement of activating isoforms of KIR or CLIR,
whereas CsA had no effect. Furthermore, CsA did not inhibit NK
cell-mediated lysis of different tumor target cells including K562
(Figure 6C), 721.221 (Figure 6D) and Jurkat (Figure 6E) cell lines,
whereas CMA reduced lysis of these target cells by 50% to 80% (Figure
5C-E). Altogether, these findings indicate that apoptosis induced via
the engagement of activating receptor is selectively CsA sensitive but
this drug does not affect the activating receptor-mediated activation
of NK cell cytolysis.
Soluble HLA-I induces IFN- by ELISA. As shown in Figure
7A, a detectable amount of IFN- was
found in culture supernatant of the representative CD158a+
NK cell clone 262 incubated with sHLA-Cw4. Covering of CD158a with a
specific mAb almost completely inhibited sHLA-Cw4-induced IFN-
production (Figure 7A), indicating that ligation of CD158a with
corresponding sHLA-I allele was necessary to deliver the activating
signal leading to IFN- production. As clone 262 expressed CD8 at low
levels, we further analyzed whether IFN- found in culture
supernatant was due to the engagement of CD8 by sHLA-Cw4. As shown in
Figure 7A, anti-CD8 mAb had no effect on sHLA-Cw4-induced IFN-
production, indicating that CD8 was not involved in activating receptor-mediated IFN- production.
The amount of IFN-
Activating forms of KIR or CLIR can deliver an apoptotic signal in
human NK cells after their engagement with the appropriate ligand
represented by sHLA. This interaction leads to production and secretion
of FasL, which in turn induces apoptosis upon ligation with Fas at the
NK cell surface. This phenomenon is accompanied by the production of
the proinflammatory cytokine IFN- The physiological significance of the presence of activating receptor at the NK cell surface specific for discrete HLA-I allele is still debated.1-3 Conceivably, these activating receptors react with the same HLA-I allele reacting with their inhibiting counterpart, but their engagement can induce the activation of NK cell-mediated functional activities such as cytolysis and cytokine production.1-3 Several authors have claimed that, to avoid autologous tissue cell damage induced by activating receptor-triggered cytolysis, the inhibiting receptors for the HLA-I can down-regulate this effect because the inhibitory signal via KIR and/or CLIR should overcome the triggering signal via their activating counterpart.1-3 If this is the case, because the HLA-I NK cell receptors seem to recognize specific HLA-I allele,1-3 NK cells should bear at the same time inhibiting and activating receptors specific for the same HLA-I allele; otherwise, the interaction of different HLA-I alleles with different counter-receptors not necessarily should take place in close proximity at the NK cell surface in order to shut down cytolysis initiated upon the engagement of activating receptor. In fact, it has been stated that inhibiting signal can switch off the activating one only if these occur closely in NK cells.1-3 Among the NK cell clones analyzed in this and previous studies8-13 we found that it is not exceptional to find NK cell clones that express an activating receptor for one HLA-I allele and inhibiting receptors for other HLA-I alleles. Indeed, we found NK cell clones with activating receptor form of KIR but CLIR+, and vice versa, without any detectable expression (both in immunofluorescence and functional assays) of known inhibiting form of KIR (not shown). In addition, although to a very low frequency (in our culture conditions) some NK cell clones with only activating forms of KIR and CLIR can be found. In these instances, it would be very hard to block NK cell-mediated cytolysis of HLA-I+ autologous cells bearing the appropriate counter-receptor. Our present results can explain, at the same time, because NK cell clones with activating receptor do not usually exist at higher frequencies and because they do not kill all autologous cells. Indeed, a certain amount ranging from 0.5 to 2 µg/mL sHLA-I (composed of a mixture of HLA-A, -B, and -C alleles) is present in serum of healthy donors,17-19,27,41 this amount would be enough to induce apoptosis of activated NK cells with activating receptor without any NK cell interaction with autologous cells. In addition, during the interaction with self-HLA-I+ tissue cells, activating receptor on NK cells may deliver the apoptotic signal, thus leading to autolimitation of any self-reaction. If this were true, what is the physiological significance of activating receptor on NK cells? One can hypothesize that activating receptor plays a role in the elimination of tumor cells. Indeed, this study and others show that when tumor cells express the appropriate self-HLA-I antigens, it is possible that the engagement of activating receptor for HLA-I can efficiently trigger cytolysis.8-13 Thus, NK cells kill self-tumor target cells by means such as perforins and granzymes, and the consequent up-regulation of production and secretion of FasL leading to NK cell apoptosis can switch off innate immune response. Recently, several receptors responsible for NK cell-mediated cytolysis
have been identified.4,5,42 These receptors are represented by natural cytotoxicity receptors (NCR), including NKp30,
NKp44, and NKp46 molecules,4 which are specifically expressed only by NK cells, and NKG2D5,42 that is
present on NK cells and on cytolytic lymphocytes bearing Notably, we found that FasL-induced apoptosis of NK cells is strongly reduced by the immunosuppressive drug CsA. Indeed, CsA can block FasL expression induced via T-cell antigen receptor in cytolytic CD8+ T-cell clones.45 Thus, CsA treatment of NK cell clones with activating receptor may be a tool to maintain killing of autologous tumor target cells without the elimination of these really potent cytolytic effector cells. In fact, CsA did not inhibit activating receptor-mediated cytolysis as well as triggering of NK cells via CD16 (this study) or other activating NK cell receptors as CD69 (not shown), suggesting that CsA did not affect NK cell-mediated killing. However, it has been reported that cytolytic effector cells can lyse tumor target cells by 2 independent mechanisms: the first is represented by degranulation of perforin/granzyme, whereas the second one is FasL mediated. In fact, several tumor target cells express at the cell surface Fas antigen and can die upon Fas engagement by FasL.25,46-48 CsA administration could then block the second cytolytic pathway of inducing tumor target cell death. Thus, to plan a CsA treatment of patients affected by neoplasia, one should consider that a certain tumor can show different sensitivity to cytolysis mediated via the 2 above-mentioned mechanisms. In fact, one should first define whether a correlation exists between tumor histotypes and their sensitivity to CsA-treated NK cells in order to select which tumor is much more sensitive to cytolysis via perforin/granzymes. Secondly, CsA treatment can strongly augment the frequency of NK cells bearing activating receptor for self-HLA-I antigens and, thus, aside from the potential and wished elimination of tumor cells, it can evoke an undesired powerful autoimmune reaction. Our findings also indicate a possible mechanism of tumor escape. In
fact, tumor cells can shed sHLA-I molecules, which upon interaction
with activating receptor for HLA-I on the NK cell surface may induce
and secrete FasL, which in turn evokes NK cell apoptosis. This effect
could take place anywhere In addition, it is well known that NK cells express CD8, another
receptor for a monomorphic portion of HLA-I. Recently, we have
demonstrated that the engagement of CD8 induces NK cell apoptosis via
FasL-Fas interaction.6 Indeed, we found a direct
correlation between the level of CD8 expression on a given clone with
the degree of sHLA-I-induced NK cell apoptosis. On this basis, we defined that only NK cell clones with intermediate or bright expression of CD8 were susceptible to sHLA-I-mediated apoptosis.6
Furthermore, we observed that the same NK cell clone could increase the
expression of CD8 during the culture period, thus increasing its
susceptibility to sHLA-I-mediated apoptosis. Herein, we could not find
a correlation between the level of expression of activating receptor
and the degree of their induced apoptosis (not shown). In fact,
the amount of a given activating receptor for HLA-I remained constant
along the culture period analyzed (4 to 8 weeks; not shown).
Altogether, these findings would suggest that down-regulation of NK
cell-mediated functional activities consequent to apoptosis may be
determined by 2 distinct types of HLA-I receptors with different
regulation of cell surface expression and be able to recognize peculiar
portions of HLA-I. In fact, it has been demonstrated that CD8 can
recognize the
Submitted April 30, 2002; accepted July 9, 2002.
Prepublished online as Blood First Edition Paper, July 18, 2002; DOI 10.1182/blood-2002-04-1284.
Supported in part by grants from Ministero della Sanità (2000-2002) and from Associazione Italiana per la Ricerca sul Cancro (AIRC2002) (A.P.); Istituto Superiore di Sanità (ISS) AIDS project (M.R.Z.), and MURST National Program 2000 MN06118858-001 (F.P.). G.M.S. is a fellow of Federazione Italiana per la Ricerca sul Cancro (FIRC).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Alessandro Poggi, Laboratory of Immunology, National Institute for Cancer Research (IST), c/o CBA, Torre A1, Largo R. Benzi, 10, 16132 Genoa, Italy; e-mail: poggi{at}vega.cba.unige.it.
1. Moretta A, Bottino C, Vitale M, et al. Receptors for HLA-class I molecules in human natural killer cells. Annu Rev Immunol. 1996;14:619-648[CrossRef][Medline] [Order article via Infotrieve]. 2. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-393[CrossRef][Medline] [Order article via Infotrieve]. 3. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1999;17:875-904[CrossRef][Medline] [Order article via Infotrieve]. 4. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223[CrossRef][Medline] [Order article via Infotrieve].
5.
Bauer S, Groh V, Wu J, et al.
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Science.
1999;285:727-729
6.
Spaggiari GM, Contini P, Carosio R, et al.
Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by CD94/NKG2A complex and KIR2D.
Blood.
2002;99:1706-1714
7.
Madelboin O, Davis DM, Reyburn HT, et al.
Enhancement of class-II-restricted T cell responses by costimulatory NK receptors for class I MHC proteins.
Science.
1996;274:2097-2100 8. Bottino C, Sivori S, Vitale M, et al. A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. Eur J Immunol. 1996;26:1816-1824[Medline] [Order article via Infotrieve].
9.
Madelboim O, Kent S, Davis DM, et al.
Natural killer activating receptors trigger interferon 10. Cantoni C, Biassoni R, Pende D, et al. The activating form of CD94 receptor complex: CD94 covalently associates with the Kp39 protein that represents the product of the NKG2-C gene. Eur J Immunol. 1998;28:327-338[CrossRef][Medline] [Order article via Infotrieve]. 11. Perez-Villar JJ, Melero I, Rodriguez A, et al. Functional ambivalence of the Kp43 (CD94) NK cell-associated surface antigen. J Immunol. 1995;154:5779-5788[Abstract].
12.
Warren H, Campbell AJ, Waldron JC, Lanier LL.
Biphasic response of NK cells expressing both activating and inhibitory killer Ig-like receptors.
Int Immunol.
2001;13:1043-1052
13.
Poggi A, Tomasello E, Revello V, et al.
p40 regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes.
Int Immunol.
1997;9:1271-1279
14.
Namekawa T, Snyder MR, Yen J-H, et al.
Killer cell activating receptors function as costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis.
J Immunol.
2000;165:1138-1145 15. Zavazava N. Soluble HLA class I molecules: biological significance and clinical implications. Mol Med Today. 1998;4:116-121[CrossRef][Medline] [Order article via Infotrieve]. 16. Zavazava N, Kronke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med. 1996;2:1005-1010[CrossRef][Medline] [Order article via Infotrieve]. 17. Puppo F, Scudelletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today. 1995;16:124-127[CrossRef][Medline] [Order article via Infotrieve]. 18. Puppo F, Indiveri F, Scudelletti M, Ferrone S. Soluble HLA antigens: new roles and uses. Immunol Today. 1997;18:154-155[CrossRef][Medline] [Order article via Infotrieve]. 19. Puppo F, Brenci S, Montinaro E, et al. Inhibition of alloreactive cytotoxic T cell activity by HIV-positive sera: potential role of circulating soluble HLA class I molecules. AIDS Res Hum Retroviruses. 1994;10:1061-1064[Medline] [Order article via Infotrieve].
20.
Ida H, Robertson MJ, Voss S, Ritz J, Anderson P.
CD94 ligation induces apoptosis in a subset of IL-2-stimulated NK cells.
J Immunol.
1997;159:2154-2160 21. Poggi A, Pella N, Morelli L, et al. p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans. Eur J Immunol. 1995;25:369-376[Medline] [Order article via Infotrieve].
22.
Moretta A, Poggi A, Pende D, et al.
CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor
23.
Furuke K, Shiraishi M, Mostowski HS, Bloom ET.
Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nuclear factors of activated T cell-dependent pathway.
J Immunol.
1999;162:1988-1993 24. Woo J-T, Shinohara C, Sakai K, et al. Isolation, characterization and biological activities of concanamycins as inhibitors of lysosomal acidification. J Antibiot. 1998;45:1108-1116. 25. Takaoka T, Shinohara N, Takayama H, et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol. 1996;156:3686.
26.
Zocchi MR, Rubartelli A, Morgavi P, Poggi A.
HIV-1 Tat inhibits human natural killer cell function by blocking L-type calcium channels.
J Immunol.
1998;161:2938-2943 27. Taswell C. Limiting dilution assay for the determination of immunocompetent cell frequencies, I: data analysis. J Immunol. 1981;126:1614-1619[Abstract]. 28. Puppo F, Costa M, Contini P, et al. Determination of soluble HLA-G and HLA-A, -B, and -C molecules in pregnancy. Transplant Proc. 1999;31:1841-1843[CrossRef][Medline] [Order article via Infotrieve].
29.
Puppo F, Contini P, Ghio M, et al.
Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas (CD95)+ T lymphocytes.
Int Immunol.
2000;12:195-203 30. Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999;18:4250-4260[CrossRef][Medline] [Order article via Infotrieve]. 31. Braud V, Jones EY, McMichael AJ. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol. 1997;27:1164-1169[Medline] [Order article via Infotrieve].
32.
Wainwright SD, Biro PA, Holmes CH.
HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib protein with a restricted expression pattern.
J Immunol.
1996;164:319-328
33.
Pietra G, Romagnani C, Falco M, et al.
The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR
34.
Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE.
HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences.
J Immunol.
1998;160:4951-4960 35. Shimizu Y, Gerarghty DE, Koller B, et al. Transfer and expression of three cloned human non-HLA-A, -B, -C class I histocompatibility complex genes in mutant lymphoblastoid cells. Proc Natl Acad Sci U S A. 1998;85:227-231. 36. Shimizu Y, DeMars R. Production of human cells expressing individual transferred HLA-A, -B, -C genes using an HLA-A, -B, -C null human cell line. J Immunol. 1989;142:3320-3328[Abstract]. 37. Lepin EJ, Bastin JM, Allan DS, et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol. 2000;30:3552-3561[CrossRef][Medline] [Order article via Infotrieve]. 38. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptor CD94/NKG2A, B and C. Nature. 1998;391:795-799[CrossRef][Medline] [Order article via Infotrieve].
39.
Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG.
Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis.
J Exp Med.
1998;187:813-818
40.
Lee N, Llano M, Carretero M, et al.
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.
Proc Natl Acad Sci U S A.
1998;95:5199-5204 41. Bresciani A, Pirozzi G, Spera M, et al. Increased levels of serum HLA class I antigens in patients with systemic lupus erythematosus: correlation with disease activity. Tissue Antigens. 1998;52:44-50[Medline] [Order article via Infotrieve]. 42. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol. 2002;14:306-311[CrossRef][Medline] [Order article via Infotrieve]. 43. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol. 2002;12:3-13[CrossRef][Medline] [Order article via Infotrieve].
44.
Azzoni L, Anegon I, Calabretta B, Perussia B.
Ligand binding to Fc 45. Anel A, Buferne M, Boyer C, Schmitt-Verhulst AM, Golstein P. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocytes is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur J Immunol. 1994;24:2469-2476[Medline] [Order article via Infotrieve]. 46. Eischen CM, Leibson PJ. Role for NK-cell-associated Fas ligand in cell-mediated cytotoxicity and apoptosis. Res Immunol. 1997;148:164-169[CrossRef][Medline] [Order article via Infotrieve].
47.
Fuller CL, Ravichandran KS, Braciale VL.
Phosphatidylinositol 3-kinase-dependent and independent cytolytic effector functions.
J Immunol.
1999;162:6337-6340 48. Kagi D, Ledermann B, Burki K, et al. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunogical protection and pathogenesis in vivo. Annu Rev Immunol. 1996;14:207-232[CrossRef][Medline] [Order article via Infotrieve].
49.
Salter RD, Norment AM, Chen BP, et al.
Polymorphism in the
50.
Connolly JM, Hansen TH, Ingold AL, Potter TA.
Recognition by CD8 on cytotoxic T lymphocytes is ablated by several substitutions in the class I
51.
Salter RD, Benjamin RJ, Wesley PK, et al.
A binding site for the T-cell co-receptor CD8 on the
52.
Fayen J, Huang JH, Meyerson H.
Class I MHC
53.
Sun J, Leahy DJ, Kavathas PB.
Interaction between CD8 and major histocompatibility complex (MHC) class I mediated by multiple contact surfaces that include the
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. K. Moesta, L. Abi-Rached, P. J. Norman, and P. Parham Chimpanzees Use More Varied Receptors and Ligands Than Humans for Inhibitory Killer Cell Ig-Like Receptor Recognition of the MHC-C1 and MHC-C2 Epitopes J. Immunol., March 15, 2009; 182(6): 3628 - 3637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Bernstein, M. C. Plasterer, S. E. Schiff, C. M. R. Kitchen, S. Kitchen, and J. A. Zack CD4 Expression on Activated NK Cells: Ligation of CD4 Induces Cytokine Expression and Cell Migration J. Immunol., September 15, 2006; 177(6): 3669 - 3676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jewett, N. A. Cacalano, C. Head, and A. Teruel Coengagement of CD16 and CD94 receptors mediates secretion of chemokines and induces apoptotic death of naive natural killer cells. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 1994 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Fainardi, R Rizzo, L Melchiorri, M Castellazzi, E Paolino, M R Tola, E Granieri, and O R Baricordi Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis Multiple Sclerosis, February 1, 2006; 12(1): 2 - 12. [Abstract] [PDF]
|
|
|
|
|
|
P. Contini, M. Ghio, A. Merlo, A. Poggi, F. Indiveri, and F. Puppo Apoptosis of Antigen-Specific T Lymphocytes upon the Engagement of CD8 by Soluble HLA Class I Molecules Is Fas Ligand/Fas Mediated: Evidence for the Involvement of p56lck, Calcium Calmodulin Kinase II, and Calcium-Independent Protein Kinase C Signaling Pathways and for NF-{kappa}B and NF-AT Nuclear Translocation J. Immunol., December 1, 2005; 175(11): 7244 - 7254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Poggi, C. Prevosto, A.-M. Massaro, S. Negrini, S. Urbani, I. Pierri, R. Saccardi, M. Gobbi, and M. R. Zocchi Interaction between Human NK Cells and Bone Marrow Stromal Cells Induces NK Cell Triggering: Role of NKp30 and NKG2D Receptors J. Immunol., November 15, 2005; 175(10): 6352 - 6360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Schierloh, N. Yokobori, M. Aleman, R. M. Musella, M. Beigier-Bompadre, M. A. Saab, L. Alves, E. Abbate, S. S. de la Barrera, and M. C. Sasiain Increased Susceptibility to Apoptosis of CD56dimCD16+ NK Cells Induces the Enrichment of IFN-{gamma}-Producing CD56bright Cells in Tuberculous Pleurisy J. Immunol., November 15, 2005; 175(10): 6852 - 6860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Poggi, A.-M. Massaro, S. Negrini, P. Contini, and M. R. Zocchi Tumor-Induced Apoptosis of Human IL-2-Activated NK Cells: Role of Natural Cytotoxicity Receptors J. Immunol., March 1, 2005; 174(5): 2653 - 2660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Huang, F. Rezzoug, P. M. Chilton, H. L. Grimes, D. E. Cramer, and S. T. Ildstad Matching at the MHC class I K locus is essential for long-term engraftment of purified hematopoietic stem cells: a role for host NK cells in regulating HSC engraftment Blood, August 1, 2004; 104(3): 873 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Goodridge, C. S. Witt, F. T. Christiansen, and H. S. Warren KIR2DL4 (CD158d) Genotype Influences Expression and Function in NK Cells J. Immunol., August 15, 2003; 171(4): 1768 - 1774. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
besides other triggering molecules
expressed on NK cells including CD16, CD2, CD69, NKp30, NKp44, NKp46,
and NKG2D
(astra102, IgG1) mAb, the NKVFS1 mAb, recognizing a common epitope of CD158a and
CD158b and p50.3, and the anti-CD69 mAb (31C4, IgG2a) were produced as
described.
) or the NK cell clone 10 (activating
receptor+ CD94+) (
) was incubated with
either sHLA-Cw4 or sHLA non-A, -B, -C, and -G (that is, putative HLA-E)
for the indicated periods of time, and apoptosis was evaluated by
staining cells with FITC-annexin V. 
indicates apoptosis of the NK
cell clone 255 incubated with medium alone. Results are expressed as
the percentage of apoptotic cells that are annexin V+ but
PI
indicates percentage of maximal apoptosis of the NK cell clone 45 incubated for 48 hours in medium alone. (B) Amount of sFasL present in
culture supernatant recovered after 24 hours of incubation under the
experimental conditions described in panel A with the same NK cell
clones. Results are expressed as nanograms per milliliter as determined
by ELISA. (C) Concanamycin A does not affect activating
receptor-mediated apoptosis. The NK cell clone 12 (p50.3+
activating) was incubated with sHLA-Cw3 or GAM-coated beads (4 per cell) after staining with anti-p50 mAb (1 µg/mL) (p50.3-XL) for
48 hours in the presence or absence of 3 µg/mL concanamycin A or with
500 ng/mL CsA and stained with FITC-annexin V. "nil" indicates
apoptosis in medium alone. Results are expressed as the percentage of
apoptotic cells (FITC-annexin V+ but PI
) or in the
presence of either 3 µg/mL CMA (
) for 24 hours alone or in the presence of increasing
doses of CsA (5, 50, 500 ng/mL). 
T-cell receptor (TCR).